| Literature DB >> 29494416 |
Jan Vollert1,2, Walter Magerl2, Ralf Baron3, Andreas Binder3, Elena K Enax-Krumova1,4, Gerd Geisslinger5,6, Janne Gierthmühlen3, Florian Henrich2, Philipp Hüllemann3, Thomas Klein2, Jörn Lötsch5, Christoph Maier1, Bruno Oertel6, Sigrid Schuh-Hofer2, Thomas R Tölle7, Rolf-Detlef Treede2.
Abstract
As an indirect approach to relate previously identified sensory phenotypes of patients suffering from peripheral neuropathic pain to underlying mechanisms, we used a published sorting algorithm to estimate the prevalence of denervation, peripheral and central sensitization in 657 healthy subjects undergoing experimental models of nerve block (NB) (compression block and topical lidocaine), primary hyperalgesia (PH) (sunburn and topical capsaicin), or secondary hyperalgesia (intradermal capsaicin and electrical high-frequency stimulation), and in 902 patients suffering from neuropathic pain. Some of the data have been previously published. Randomized split-half analysis verified a good concordance with a priori mechanistic sensory profile assignment in the training (79%, Cohen κ = 0.54, n = 265) and the test set (81%, Cohen κ = 0.56, n = 279). Nerve blocks were characterized by pronounced thermal and mechanical sensory loss, but also mild pinprick hyperalgesia and paradoxical heat sensations. Primary hyperalgesia was characterized by pronounced gain for heat, pressure and pinprick pain, and mild thermal sensory loss. Secondary hyperalgesia was characterized by pronounced pinprick hyperalgesia and mild thermal sensory loss. Topical lidocaine plus topical capsaicin induced a combined phenotype of NB plus PH. Topical menthol was the only model with significant cold hyperalgesia. Sorting of the 902 patients into these mechanistic phenotypes led to a similar distribution as the original heuristic clustering (65% identity, Cohen κ = 0.44), but the denervation phenotype was more frequent than in heuristic clustering. These data suggest that sorting according to human surrogate models may be useful for mechanism-based stratification of neuropathic pain patients for future clinical trials, as encouraged by the European Medicines Agency.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29494416 DOI: 10.1097/j.pain.0000000000001190
Source DB: PubMed Journal: Pain ISSN: 0304-3959 Impact factor: 6.961